The effect of highly active antiretroviral therapy on the survival of HIV-infected children in a resource-deprived setting: a cohort study
about
Optimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years oldA Modified P1 Moiety Enhances in vitro Antiviral Activity against Various Multi-Drug-Resistant HIV-1 Variants and in vitro CNS Penetration Properties of a Novel Nonpeptidic Protease Inhibitor, GRL-10413When to start antiretroviral therapy in children aged 2-5 years: a collaborative causal modelling analysis of cohort studies from southern AfricaSurvival Outcomes in a Pediatric Antiretroviral Treatment Cohort in Southern MalawiThe Impact of Sparse Follow-up on Marginal Structural Models for Time-to-Event Data.Predictors of Hospitalization among Children on ART in Ethiopia: a Cohort study.Development, calibration and performance of an HIV transmission model incorporating natural history and behavioral patterns: application in South Africa.Mortality and Loss to Follow up Before Initiation of Antiretroviral Therapy Among HIV-Infected Children Eligible for HIV Treatment.Tuberculosis Immune Reconstitution Inflammatory Syndrome in children initiating Antiretroviral Therapy for HIV infection: A systematic literature review"Let's talk about sex": a qualitative study of Rwandan adolescents' views on sex and HIVCombining directed acyclic graphs and the change-in-estimate procedure as a novel approach to adjustment-variable selection in epidemiology.Retention in care of HIV-infected children from HIV test to start of antiretroviral therapy: systematic review.Living situation affects adherence to combination antiretroviral therapy in HIV-infected adolescents in Rwanda: a qualitative study.Age-specific and sex-specific weight gain norms to monitor antiretroviral therapy in children in low-income and middle-income countries.A novel tricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor, GRL-0739, effectively inhibits the replication of multidrug-resistant HIV-1 variants and has a desirable central nervous system penetration property in vitro.[Impact of antiretroviral therapy on the biological profile of HIV positive children followed-up at Yaounde University Hospital in Cameroon].Tuberculosis in Pediatric Antiretroviral Therapy Programs in Low- and Middle-Income Countries: Diagnosis and Screening Practices.Implementation and Operational Research: Maternal Combination Antiretroviral Therapy Is Associated With Improved Retention of HIV-Exposed Infants in Kinshasa, Democratic Republic of Congo.Early infant diagnosis of HIV infection in Zambia through mobile phone texting of blood test results.Non-Uptake of HIV Testing in Children at Risk in Two Urban and Rural Settings in Zambia: A Mixed-Methods Study.Retention of HIV-Infected Children in the First 12 Months of Anti-Retroviral Therapy and Predictors of Attrition in Resource Limited Settings: A Systematic Review.High completion of isoniazid preventive therapy among HIV-infected children and adults in Kinshasa, Democratic Republic of Congo.Factors that lead to changes in sexual behaviours after a negative HIV test: protocol for a prospective cohort study in Kinshasa.Design, synthesis, biological evaluation and X-ray structural studies of HIV-1 protease inhibitors containing substituted fused-tetrahydropyranyl tetrahydrofuran as P2-ligands.Simple markers for the detection of severe immunosuppression in children with HIV infection in highly resource-scarce settings: experience from the Democratic Republic of Congo.Outcomes of antiretroviral therapy in children in Asia and Africa: a comparative analysis of the IeDEA pediatric multiregional collaboration.Structure-based design of potent HIV-1 protease inhibitors with modified P1-biphenyl ligands: synthesis, biological evaluation, and enzyme-inhibitor X-ray structural studiesC-5-Modified Tetrahydropyrano-Tetrahydofuran-Derived Protease Inhibitors (PIs) Exert Potent Inhibition of the Replication of HIV-1 Variants Highly Resistant to Various PIs, including DarunavirGRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro.Mortality and treatment outcomes of China's National Pediatric antiretroviral therapy program.Implementation and Operational Research: Decentralization Does Not Assure Optimal Delivery of PMTCT and HIV-Exposed Infant Services in a Low Prevalence Setting.Impact of WHO 2010 Guidelines on Antiretroviral Therapy Initiation among Patients with HIV-Associated Tuberculosis in Clinics with and without Onsite HIV Services in the Democratic Republic of CongoHigh retention among HIV-infected children in Rwanda during scale-up and decentralization of HIV care and treatment programs, 2004 to 2010.Retention of HIV-infected children on antiretroviral treatment in HIV care and treatment programs in Kenya, Mozambique, Rwanda, and Tanzania.Predictors of loss to follow-up after engagement in care of HIV-infected children ineligible for antiretroviral therapy in an HIV cohort study in India.Description of the cascade of care and factors associated with attrition before and after initiating antiretroviral therapy of HIV infected children in a cohort study in IndiaBarriers to uptake of early infant HIV testing in Zambia: the role of intimate partner violence and HIV status disclosure within couples.Reasons for hospitalization in HIV-infected children in West AfricaMortality and clinical outcomes in children treated with antiretroviral therapy in four African vertical programmes during the first decade of paediatric HIV care, 2001-2010.Pediatric HIV care and treatment services in Tanzania: implications for survival.
P2860
Q24197527-795E5398-A492-4560-8AC1-D5F147C6CC0AQ27728053-7E527BD2-677A-460D-B7CC-DAC34F327966Q28535251-4640C93F-F3DF-4A64-BDA8-826272A2551BQ28553184-47DFE36C-CE9F-4878-A2D3-37016B58D490Q31026915-2DCDEA2E-87F7-481C-AE2E-2A11B59C6FE6Q33596123-593EBEFA-A641-4CCD-BFAE-CCBF545EAE62Q33670446-1F335CDE-A794-4CDF-82CB-19CBDD9A2BD8Q33851192-CF3F6DF2-14D4-4DBB-9861-4F3AC0A874FDQ34003099-FD0F4AF2-B04A-4C0E-B432-D5BC25ED512CQ34004750-0EEF2B80-69C1-4AE6-A557-EF23E5D0815FQ34443769-74BEBEE1-0780-4090-B192-F63B35C451C2Q34598728-435CDF2F-B1D9-463C-B463-6B8DF2483473Q34661851-F14ABDFD-82E4-43C8-8419-E500AEE1FDBFQ35248842-81D1CDF6-A2AE-46C1-904C-5B3B7848AD17Q35386013-A2596E26-642D-41AF-9637-42B7FE8F8E54Q35748231-487D840B-8072-4A55-9D9D-4A0E3D3A37F3Q35788768-1D4BF816-E175-45C2-AA28-FD4AE48DE780Q35863937-9C31640E-699C-40C4-A50D-87B9CC0C85B6Q35926612-364AA85C-27C6-4DFA-A381-EBDF9D6F88B1Q36046303-042DBE47-6E09-444F-9E07-28E3753ECBCCQ36046415-298AACB4-2AA5-40A4-920B-1F982A124BC2Q36049719-F66E8D5E-9390-481D-96ED-D77DC776F642Q36083376-6899F905-D276-4997-9F2D-FB10CEB3489DQ36338687-E479750D-6057-41F1-853A-D759712863B9Q36504397-72D488AF-E6B8-4460-BAC6-63A73A3AC4C9Q36565583-44B204CD-7ED6-4FBC-8886-17E02BF68476Q36613702-69F3A61A-2173-4198-B626-758F0AA13780Q36736848-C3A9C727-2DDC-415E-8847-CADA723264BFQ36785919-CA624BBE-8CEA-41B7-A649-CD07D6AC8D42Q36853859-38802C30-7588-4CD2-857F-B85131D8DFF3Q36867733-D650581C-013E-4DAB-9352-4C9A647AF314Q37195317-A6D8A850-0D18-4665-BE84-4235B5BB8396Q37343714-7F3831EE-0518-452F-8B97-39E80BDBA9E4Q37390909-2B7411F2-9300-4EFE-98CF-5F17D3358CCDQ37640066-54BD0EA3-771D-4FEE-8AE3-C0964EDC61C3Q37652234-A35FCD71-582C-486A-93A8-5870B3B56BB1Q37713666-1A7E5685-0CCB-4EF1-9F51-A3233202AB09Q37723712-FBD5B69E-405E-4F04-97AE-9D8287D72B8AQ38851825-23AA5C79-9A27-4863-9699-237924287D24Q39477797-F2BADB8E-1D1B-47C1-9032-D1245629BE76
P2860
The effect of highly active antiretroviral therapy on the survival of HIV-infected children in a resource-deprived setting: a cohort study
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
The effect of highly active an ...... prived setting: a cohort study
@ast
The effect of highly active an ...... prived setting: a cohort study
@en
type
label
The effect of highly active an ...... prived setting: a cohort study
@ast
The effect of highly active an ...... prived setting: a cohort study
@en
prefLabel
The effect of highly active an ...... prived setting: a cohort study
@ast
The effect of highly active an ...... prived setting: a cohort study
@en
P2093
P2860
P50
P1433
P1476
The effect of highly active an ...... prived setting: a cohort study
@en
P2093
Andrew Edmonds
Faustin Kitetele
Jean Lusiama
Stephen R Cole
Yori Matumona
P2860
P304
P356
10.1371/JOURNAL.PMED.1001044
P407
P577
2011-06-14T00:00:00Z